Anika Therapeutics, Inc.

General ticker "ANIK" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $305.0M (TTM average)

Anika Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -6.4%.

Estimated limits based on current volatility of 5.6%: low 12.25$, high 13.71$

Factors to consider:

  • US accounted for 68.8% of revenue in the fiscal year ended 2024-12-31
  • Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [10.79$, 21.74$]
  • 2025-12-31 to 2026-12-31 estimated range: [8.98$, 18.43$]

Financial Metrics affecting the ANIK estimates:

  • Negative: Non-GAAP EPS, $ of -0.42 <= 0.04
  • Negative: negative Net income
  • Positive: -0.87 < Investing cash flow per share, $ of -0.57
  • Negative: negative Operating income
  • Positive: Interest expense per share, $ of 0 <= 0
  • Positive: Inventory ratio change, % of -11.18 <= -1.01
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: Shareholder equity ratio, % of 75.95 > 63.75
  • Negative: Operating cash flow per share per price, % of 2.14 <= 7.09

Similar symbols

Short-term ANIK quotes

2025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-022025-05-052025-05-062025-05-072025-05-082025-05-092025-05-1211.51212.51313.51414.51515.5
Price $

Long-term ANIK plot with estimates

101520253035Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027−2−10
ANIKS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $113.83MM $120.79MM $119.91MM
Operating Expenses $110.16MM $119.95MM $125.01MM
Operating Income $3.67MM $0.84MM $-5.10MM
Non-Operating Income $0.65MM $2.31MM $2.34MM
R&D Expense $18.32MM $21.76MM $25.54MM
Income(Loss) $4.32MM $3.16MM $-2.76MM
Taxes $2.12MM $6.59MM $6.06MM
Other Income(Loss) $-17.06MM $-79.23MM $-47.56MM
Profit(Loss)* $-14.86MM $-82.67MM $-103.94MM
Stockholders Equity $285.56MM $212.26MM $153.99MM
Inventory $39.77MM $46.39MM $23.81MM
Assets $349.13MM $270.63MM $202.74MM
Operating Cash Flow $4.41MM $-1.79MM $5.40MM
Capital expenditure $7.49MM $5.43MM $7.73MM
Investing Cash Flow $-7.49MM $-5.43MM $-8.33MM
Financing Cash Flow $-4.85MM $-6.32MM $-12.73MM
Earnings Per Share** $-1.02 $-5.64 $-7.06

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.